| Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-15 14:50:25 |
Czytaj oryginał (ang.) |
| Exelixis: A Notable Quarter |
Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt. |
seekingalpha.com |
2025-05-14 18:53:34 |
Czytaj oryginał (ang.) |
| Why Exelixis Stock Is Skyrocketing Today |
Shares of Exelixis (EXEL 17.92%) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. |
fool.com |
2025-05-14 15:33:36 |
Czytaj oryginał (ang.) |
| Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance |
Exelixis Inc. EXEL reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the consensus of 36 cents. |
benzinga.com |
2025-05-14 14:44:27 |
Czytaj oryginał (ang.) |
| EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line |
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025. |
zacks.com |
2025-05-14 14:01:20 |
Czytaj oryginał (ang.) |
| Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript |
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer P.J. Haley - Executive Vice President, Commercial Amy Peterson - Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer Dana Aftab - Executive Vice President, Discovery and Translational Research and Chief Scientific Officer Conference Call Participants Michael Schmidt - Guggenheim Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley Silvan Tuerkcan - Citizens Yaron Werber - TD Cowen Chi Fong - Bank of America Securities Akash Tewari - Jefferies Eva Fortea-Verdejo - Wells Fargo Andy Hsieh - William Blair Eason Lee - Leerink Partners Cheng Li - Oppenheimer Ashwani Verma - UBS Peter Lawson - Barclays Felix Ampomah - Stephens Operator Good day, ladies and gentlemen, and welcome to the Exelixis First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-14 00:31:51 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-13 23:01:17 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates |
Exelixis (EXEL) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago. |
zacks.com |
2025-05-13 22:20:35 |
Czytaj oryginał (ang.) |
| Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors |
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (. |
businesswire.com |
2025-05-13 22:06:00 |
Czytaj oryginał (ang.) |
| Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® demand, new patient starts and revenues,” said Michael M. Morrissey, Ph.D., President and Chie. |
businesswire.com |
2025-05-13 20:07:00 |
Czytaj oryginał (ang.) |
| Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? |
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-05-12 17:11:15 |
Czytaj oryginał (ang.) |
| Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Exelixis (EXEL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025. |
zacks.com |
2025-05-08 14:21:01 |
Czytaj oryginał (ang.) |
| Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas. RBC Capital Markets 2025 Global Healthcare Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Tuesday, May 20 in New York City. To access th. |
businesswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Exelixis (EXEL) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-02 14:55:53 |
Czytaj oryginał (ang.) |
| Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon regis. |
businesswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points |
Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America, |
investors.com |
2025-04-26 12:00:43 |
Czytaj oryginał (ang.) |
| Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? |
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results. |
zacks.com |
2025-04-25 18:30:34 |
Czytaj oryginał (ang.) |
| Here's Why Exelixis (EXEL) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-24 14:40:35 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release |
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-22 15:06:25 |
Czytaj oryginał (ang.) |
| Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-16 14:50:55 |
Czytaj oryginał (ang.) |
| 4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty |
Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria. |
zacks.com |
2025-02-25 14:10:48 |
Czytaj oryginał (ang.) |
| EXEL or TECH: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-02-24 14:45:37 |
Czytaj oryginał (ang.) |
| Why Exelixis Stock Trounced the Market on Thursday |
Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day. |
fool.com |
2025-02-21 20:31:00 |
Czytaj oryginał (ang.) |
| Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? |
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025. |
benzinga.com |
2025-02-21 15:30:43 |
Czytaj oryginał (ang.) |
| Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis plans on completing the currently ongoing $500 million stock repurchase program (SRP), announced in August 2024, in the second quarter of 2025, and commence stock repurchases under the newly authorized SRP thereafter. The February 2025 SRP is the fou. |
businesswire.com |
2025-02-20 19:05:00 |
Czytaj oryginał (ang.) |
| Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-02-20 15:45:24 |
Czytaj oryginał (ang.) |
| Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy? |
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth. |
zacks.com |
2025-02-18 12:16:17 |
Czytaj oryginał (ang.) |
| International Markets and Exelixis (EXEL): A Deep Dive for Investors |
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock. |
zacks.com |
2025-02-17 12:16:29 |
Czytaj oryginał (ang.) |
| Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that efficacy benefits with CABOMETYX in combination with Opdivo were sustained long term. These results, including subgro. |
businesswire.com |
2025-02-15 13:10:00 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-02-14 12:41:31 |
Czytaj oryginał (ang.) |
| EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus |
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025. |
zacks.com |
2025-02-12 16:51:19 |
Czytaj oryginał (ang.) |
| Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow |
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model potential approval of cabozantinib for neuroendocrine tumors. EXEL's STELLAR-303 trial of zanzalintinib in metastatic colorectal cancer is expected to produce a result in H2'25, but the outcome is challenging to predict. |
seekingalpha.com |
2025-02-12 11:04:23 |
Czytaj oryginał (ang.) |
| Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript |
Exelixis, Inc. (NASDAQ:EXEL ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Mike Morrissey - President & Chief Executive Officer Chris Senner - Chief Financial Officer PJ Haley - Executive Vice President, Commercial Amy Peterson - Chief Medical Officer Dana Aftab - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Sean Laaman - Morgan Stanley David Lebowitz - Citi Gregory Renza - RBC Capital Markets Eva Fortea-Verdejo - Wells Fargo Jason Gerberry - Bank of America Securities Andy Hsieh - William Blair Yaron Werber - TD Cowen Peter Lawson - Barclays Stephen Willey - Stifel Ash Verma - UBS Sudan Loganathan - Stephens Operator Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today. |
seekingalpha.com |
2025-02-11 22:24:59 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-11 21:01:27 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates |
Exelixis (EXEL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.33 per share a year ago. |
zacks.com |
2025-02-11 20:26:13 |
Czytaj oryginał (ang.) |
| Exelixis Posts 63.7% Profit Surge |
Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year-over-year figures by 18.2%. |
fool.com |
2025-02-11 19:16:13 |
Czytaj oryginał (ang.) |
| Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis delivered a strong fourth quarter of 2024, positioning us well to maximize success in 2025,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “Due to the continu. |
businesswire.com |
2025-02-11 18:05:00 |
Czytaj oryginał (ang.) |
| 2 Stocks to Buy With Less Than $40 |
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items. |
fool.com |
2025-02-10 11:00:00 |
Czytaj oryginał (ang.) |
| EXEL or TECH: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-02-06 14:40:29 |
Czytaj oryginał (ang.) |
| 4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets |
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria. |
zacks.com |
2025-02-06 13:36:13 |
Czytaj oryginał (ang.) |
| EXEL vs. INCY: Which Stock Should Value Investors Buy Now? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-25 14:41:24 |
Czytaj oryginał (ang.) |
| Exelixis downgraded to Market Perform from Outperform at BMO Capital |
BMO Capital downgraded Exelixis to Market Perform from Outperform with a price target of $40, up from $36. The "main driver of our thesis has played out positively," as a judge ruled in the MSN II litigation case for cabozantinib patents, ruling that Exelixis' '349 patent is not invalid but that MSN's ANDA is not infringing, notes the analyst, who now sees limited upside to the story in 2025 beyond zanzalintinib's readout in colorectal cancer. The firm has raised its target on zanzalintinib's probability of success in CRC, which it now pegs at 50%, but views the success of the trial as "a toss-up" given the history of cabometyx's combination with Tecentriq in this indication, the analyst added. |
https://thefly.com |
2024-12-19 18:15:17 |
Czytaj oryginał (ang.) |
| 4 Biotech Stocks Most Wall Street Analysts Are Bullish About |
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals. |
zacks.com |
2024-12-19 16:25:23 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why |
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-12-09 15:46:22 |
Czytaj oryginał (ang.) |
| EXEL or INCY: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-09 14:46:25 |
Czytaj oryginał (ang.) |
| 2 Biotech Stocks to Buy Hand Over Fist in December |
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. |
fool.com |
2024-12-07 10:45:00 |
Czytaj oryginał (ang.) |
| Here's Why Exelixis (EXEL) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-29 12:57:30 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue? |
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-28 14:36:00 |
Czytaj oryginał (ang.) |
| Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City. Citi 2024 Global Healthcare Conference: Exelixis is scheduled to present at 1:45 p.m. ET / 10:45 a.m. PT on Wednesday, December 4 in Miami. To access the w. |
businesswire.com |
2024-11-27 18:05:00 |
Czytaj oryginał (ang.) |
| ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion |
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025. |
zacks.com |
2024-11-27 14:30:20 |
Czytaj oryginał (ang.) |
| Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors |
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA is based on the final re. |
businesswire.com |
2024-11-26 18:05:00 |
Czytaj oryginał (ang.) |
| End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL) |
As the calendar winds down, the stock market often heats up. The last five weeks of the year have historically shown a bullish seasonal pattern, fueled by holiday optimism, institutional portfolio adjustments, and a tendency for investors to position themselves for the upcoming year. |
zacks.com |
2024-11-26 15:35:19 |
Czytaj oryginał (ang.) |
| Exelixis Stock Surges 25% in a Month: Time to Buy or Sell? |
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth. |
zacks.com |
2024-11-25 16:25:24 |
Czytaj oryginał (ang.) |
| Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-25 12:45:50 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love Exelixis (EXEL) |
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-11-21 15:46:08 |
Czytaj oryginał (ang.) |
| EXEL vs. CSLLY: Which Stock Is the Better Value Option? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-11-21 14:41:26 |
Czytaj oryginał (ang.) |
| Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks |
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases. |
zacks.com |
2024-11-19 10:20:29 |
Czytaj oryginał (ang.) |
| What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now? |
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-11-11 15:06:11 |
Czytaj oryginał (ang.) |
| Here's Why Exelixis (EXEL) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-11 12:51:14 |
Czytaj oryginał (ang.) |
| Here's Why Exelixis (EXEL) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-07 12:45:46 |
Czytaj oryginał (ang.) |